Deutsche Bank Ag\ Athira Pharma, Inc. Transaction History

Deutsche Bank Ag\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $29,733 - $45,230	-12,599 Reduced 38.45%	20,171 $59,000
Q1 2023 May 15, 2023	BUY	$2.26 - $4.22 $43,073 - $80,428	19,059 Added 139.01%	32,770 $81,000
Q4 2022 Feb 13, 2023	SELL	$2.76 - $3.71 $41,157 - $55,323	-14,912 Reduced 52.1%	13,711 $43,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $37,729 - $50,992	12,877 Added 81.78%	28,623 $85,000
Q2 2022 Aug 11, 2022	SELL	$2.74 - $13.43 $6,071 - $29,760	-2,216 Reduced 12.34%	15,746 $48,000
Q1 2022 May 13, 2022	SELL	$8.96 - $13.51 $18,144 - $27,357	-2,025 Reduced 10.13%	17,962 $242,000
Q4 2021 Feb 11, 2022	SELL	$9.17 - $16.39 $169,580 - $303,100	-18,493 Reduced 48.06%	19,987 $260,000
Q3 2021 Nov 04, 2021	BUY	$9.15 - $11.09 $141,358 - $171,329	15,449 Added 67.08%	38,480 $361,000
Q2 2021 Aug 11, 2021	BUY	$10.24 - $20.87 $148,172 - $301,988	14,470 Added 169.02%	23,031 $236,000
Q1 2021 May 13, 2021	SELL	$16.9 - $29.77 $7,655 - $13,485	-453 Reduced 5.03%	8,561 $157,000
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $148,550 - $309,180	9,014 New	9,014 $309,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.